Myelodysplastic/myeloproliferative neoplasm

Researchers are testing a drug called APR-246 combined with azacitidine in people with myeloid blood cancers that carry a TP53 mutation, including myelodysplastic syndrome, acute myeloid leukemia, myeloproliferative neoplasms, and chronic myelomonocytic leukemia. The trial aims t…

This study tested a drug called fedratinib in 25 adults with rare blood cancers (MDS/MPN and CNL). The goal was to see if the drug could shrink the spleen and improve blood counts. While not a cure, the treatment aims to control the disease and reduce symptoms.

This study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…

This study tested whether adding the drug tocilizumab to standard care could reduce the risk of graft-versus-host disease (GVHD) after a cord blood transplant in adults with blood cancers. GVHD is a serious complication where donor cells attack the patient's body. Tocilizumab blo…

This early-phase study tested a new drug called TGR-1202 combined with the standard drug ruxolitinib in 60 people with myelofibrosis or polycythemia vera. The goal was to see if the combination is safe and tolerable. Participants either had not responded well to ruxolitinib alone…

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This study tested a combination of two drugs, ruxolitinib and azacytidine, in 121 people with myelofibrosis or related blood cancers. The goal was to see if the combo could shrink tumors or improve blood counts. While the treatment aims to control the disease, it is not a cure, a…

This early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…

This study looked at how often people with certain blood cancers or related conditions have an acquired deficiency of an enzyme called pyruvate kinase, which can cause anemia. Researchers took a single blood sample from 18 participants to measure enzyme activity and check for rel…

This study looked at 308 people with myelodysplastic syndromes (MDS) who had a stem cell transplant. Researchers identified each patient's unique genetic mutations and then monitored those mutations in blood and bone marrow samples after transplant. The goal was to see if rising …

This completed study enrolled over 2,100 people with or suspected of having myelodysplastic syndromes (MDS), a group of blood disorders. Researchers collected medical data, blood, and tissue samples over time to track how the disease develops and progresses. The goal was to creat…

This study enrolled 349 people with myelodysplastic syndromes (MDS) to see how certain gene mutations affect survival. Researchers collected blood samples at diagnosis and tracked patients over time. The goal was to understand which mutations are linked to better or worse outcome…